Publications by authors named "Jaikumar Ramamurthy"
Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B-cell non-Hodgkin lymphoma in LMIC setting.
Venkatraman Radhakrishnan Venkatakrishnan Kritthivasan Balaji Thiruvengadam Kothandan Prasanth Srinivasan Gargi Das Jaikumar Ramamurthy
Pediatr Blood Cancer
December 2023
Background And Objectives: Pediatric B-cell non-Hodgkin lymphomas (NHL) in low- and middle-income countries (LMICs) have historically had inferior outcomes due to higher treatment-related mortality (TRM) and relapses. To address this issue, we evaluated the impact of reducing chemotherapy dose intensity by 25% and adding rituximab on outcomes in pediatric B-NHL.
Patients And Methods: Patients, less than 18 years of age with group B and C disease as per the Lymphome Malin de Burkitt (LMB) risk stratification were enrolled between September 2017 and October 2022.
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Indian J Hematol Blood Transfus
October 2018
Article Synopsis
- Rasburicase is a medication used to lower uric acid levels in patients at risk of tumor lysis syndrome (TLS), and this study examines the effectiveness of a single 1.5 mg dose compared to a higher daily dose over five days.
- In a study of 186 patients, including 56.4% children, the single fixed dose successfully prevented clinical and laboratory TLS in most patients receiving prophylactic treatment, suggesting it is an effective option.
- The findings indicate that the 1.5 mg dose is not only efficient in managing TLS but also more cost-effective, making it suitable for settings with limited resources.